start portlet menu bar

การขอดูเนื้อหาบนเว็บ

Display portlet menu
end portlet menu bar

Efficacy and economics of a polyvalent mastitis vaccine

หน้าหลัก ความรู้ Efficacy and economics of a polyvalent mastitis vaccine

Efficacy and economics of a polyvalent mastitis vaccine

Mastitis is an important animal disease causing decreased production and profits on dairy farms. J5 vaccines against gram negative pathogens have been used in the US for over 40 years. Since 2009 a polyvalent vaccine protecting against coliforms, Staphylococcus aureus and coagulase negative staphylococci (CNS) has been available in Europe (STARTVAC®, HIPRA). The objective of this study was to look at the efficacy of this vaccine under field conditions and to estimate the economic consequences of using this vaccine on dairy farms.

เกี่ยวกับบทความ

ผู้แต่ง

Oostenbrug H.J.H; Van Aaken, T.B.

บทสรุป

This vaccine has proven being capable of reducing clinical signs of acute coliform mastitis and reducing the reproduction ratio for more chronic mastitis pathogens. Also increased milk production with higher milk solids and reduced culling rates due to mastitis have been observed.

บริการที่เกี่ยวข้อง

ผลิตภัณฑ์ที่เกี่ยวข้อง

แบ่งปัน